

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 February 2025 (06.02.2025)



(10) International Publication Number
WO 2025/030074 A2

(51) International Patent Classification:
C07D 209/16 (2006.01) A61K 31/4045 (2006.01)

(21) International Application Number:
PCT/US2024/040667

(22) International Filing Date:
02 August 2024 (02.08.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/530,671 03 August 2023 (03.08.2023) US
18/368,143 14 September 2023 (14.09.2023) US

(71) Applicant: GILGAMESH PHARMACEUTICALS,
INC. [US/US]; 113 University Place, Suite 1019, New
York, New York 10003 (US).

(72) Inventors: KRUEGEL, Andrew Carry; c/o Gilgamesh
Pharmaceuticals, Inc., 113 University Place, Suite 1019,
New York, New York 10003 (US). LEONG, William; c/
o Gilgamesh Pharmaceuticals, Inc., 113 University Place,
Suite 1019, New York, New York 10003 (US). HE, Ya-
meng; c/o Gilgamesh Pharmaceuticals, Inc., 113 Universi-
ty Place, Suite 1019, New York, New York 10003 (US).
MACEACHERN, Lauren; c/o Gilgamesh Pharmaceuti-
cals, Inc., 113 University Place, Suite 1019, New York, New
York 10003 (US).

(74) Agent: GROLZ, Edward; Scully, Scott, Murphy & Press-
er, 400 Garden City Plaza, Suite 300, Garden City, New
York 11530 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))

WO 2025/030074 A2

(54) Title: CRYSTALLINE SALTS OF N-ETHYL-(5-FLUORO-1H-INDOL-3-YL)-N-METHYLETHAN-1-AMINE

(57) Abstract: The present disclosure relates to a crystalline *N*-ethyl-2-(5-fluoro-1*H*-indol-3-yl)-*N*-methylethan-1-amine salt select-
ed from crystalline *N*-ethyl-2-(5-fluoro-1*H*-indol-3-yl)-*N*-methylethan-1-amine monophosphate, crystalline *N*-ethyl-2-(5-fluoro-1*H*-
indol-3-yl)-*N*-methylethan-1-amine mono-*p*-tosylate, crystalline *N*-ethyl-2-(5-fluoro-1*H*-indol-3-yl)-*N*-methylethan-1-amine hemi-
malate, and crystalline *N*-ethyl-2-(5-fluoro-1*H*-indol-3-yl)-*N*-methylethan-1-amine monosuccinate, pharmaceutical compositions com-
prising same, and uses thereof for treating mood disorders.